Combination immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of two drugs (L19IL2 and ruxolitinib) for people with advanced solid tumors, specifically pancreatic, colorectal, or kidney cancer that has grown after standard treatments. The goal is to see if this combination is safe and may help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers that has spread and stopped responding to standard treatments: pancreatic (PDAC), colorectal (MSS/pMMR), or kidney (clear cell).
- You must have had at least one or two prior treatments for your cancer, depending on the type.
- You must have tumors that can be measured on a scan (at least one measurable lesion).
- You must be in fairly good general health (able to do light activities, life expectancy > 3 months).
- Your blood counts and organ function (kidney, liver) must meet certain levels, and you must test negative for tuberculosis and certain infections (HIV, hepatitis B, hepatitis C).
- You cannot have cancer spread to the brain, an active autoimmune disease, or severe heart/lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
This study tests a new combination therapy for people with advanced tumors that have not responded to other treatments. The goal is to see if the combination can shrink tumors and improve well-being.
This study tests a new combination of two drugs, aipalirovorelizumab and fruquintinib, for people with a specific type of advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.